Financing to expand the bio-technology company’s products, aimed at reducing food system footprint.
California-based bio-tech company Triplebar on Monday announced US$20 million in new funding to expand its product portfolio in food and biopharmaceuticals. Synthesis Capital led the round, which takes the firm’s cumulative funding up to $25 million, with participation from Essential Capital, Stray Dog Capital, iSelect Fund and The Production Board.
Triplebar’s Hyper-Throughput screening platform acts…
Join for free* to continue reading.
You’ll get access to all Alt-Meat has to offer including full access to our web content devoted to the meat alternatives market.
Already a member? Click here to login>>.
*Free for qualified recipients